drugset
drugset / Trial / NCT05152277

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects

NCT05152277 ↗

Phase 1 Completed 90 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindBasic science

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple subcutaneous injections of HRS9531 in healthy subjects.

Timeline

Start
2021-12-06
Primary completion
2022-08-24
Completion
2022-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown — Subcutaneous

Indications

type 2 diabetes mellitus